McKesson Raises 2026 EPS Growth Guidance to 18%, Reports $10B Cash Flow
McKesson’s net income rose 14.4% annually over three years while EPS climbed 19.6%, driving a 144% total stock return via share repurchases and steady profit growth. The company generates $10.0 billion in annual operational cash flow, maintains interest coverage of 25.2x and raised full-year adjusted EPS growth guidance to 18%.
1. Compounding Returns and Earnings Growth
McKesson’s net income expanded at a 14.4% annual rate over the past three years while EPS surged 19.6% per year, resulting in a 144% total return fueled by disciplined share buybacks and consistent profit growth.
2. Cash Flow Generation and Capital Allocation
The company directs billions of pharmaceutical units through its distribution network to generate $10.0 billion in annual operational cash flow, keeps capital expenditures at $838 million and delivers a 2.7% net shareholder yield through dividends and buybacks.
3. Strong Financial Position
With interest coverage of 25.2x and a payout funding ratio of 3.5, McKesson exhibits ample financial flexibility to service debt and sustain capital returns while pursuing strategic investments in higher-margin segments.
4. Strategic Shift and Margin Risks
While the oncology segment grew 57%, McKesson faces gross margin pressure from low-margin GLP-1 medications; the May 7 Q4 earnings call will reveal whether high-margin initiatives offset these headwinds.